38 articles, transcripts, and reports
Merck & Co., Inc. (NYSE: MRK) reported earnings and sales for the second quarter of 2021. Worldwide sales edged up 22% year-over-year to $11.4 billion…
After bringing the global economy to a grinding halt, the coronavirus pandemic is subsiding in most regions, thanks to the mass production of vaccines developed…
Merck & Co., Inc. (NYSE: MRK) Q1 2021 earnings call dated Apr. 29, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C. Frazier — Chairman and…
Merck & Co Inc (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C. Frazier — Chairman of the…
Merck & Co Inc (NYSE: MRK) Q4 2020 earnings call dated Feb. 04, 2021 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C.…
Merck & Co., Inc. (NYSE: MRK) reported weak earnings and sales for the fourth quarter of 2020. Worldwide sales edged up 5% year-over-year to $12.5…
Merck & Co. Inc. (NYSE: MRK) has decided to discontinue the development of its COVID-19 vaccine candidates after its clinical trials yielded disappointing results. Shares…
Merck (NYSE: MRK) announced the acquisition of privately-held biopharma company OncoImmune for an upfront payment of $425 million in cash with subsequent payments based on…
Merck & Co. Inc. (NYSE: MRK) Q3 2020 earnings call dated Oct. 27, 2020 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Kenneth C. Frazier — Chairman of…
Merck & Co., Inc. (NYSE: MRK) reported stronger than expected earnings and sales for the third quarter of 2020. The company’s stock gained early Tuesday…
